Updated just now · Live
Stock analysis, price data, and AI-powered insights for Monte Rosa Therapeutics Inc (GLUE).
Monte Rosa Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for GLUE.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). GLUE Stock Intelligence Report. [stoxpulse.com/stocks/glue]
Disclaimer: The information on this page about Monte Rosa Therapeutics Inc (GLUE) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Monte Rosa Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Monte Rosa To Present Preclinical Data Highlightin...
1d ago
Monte Rosa Therapeutics Presents Preclinical Data ...
1d ago
StoxPulse AI results for GLUE: Pulse Score 51.5/100. Primary sentiment trends from 2 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$1.59B
P/E Ratio
—
EPS
—
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Monte Rosa To Present Preclinical Data Highlighting Potential Of CCNE1-Directed MGD, MRT-55811, To Treat CCNE1-Amplified Solid Tumors At AACR Annual Meeting 2026
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors